Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
BND-35 -001 trial includes unique combination arms with anti-EGFR (cetuximab) and anti-PD-1/PD-L1, in selected indications MISGAV, Israel June 24, 2024 /PRNewswire/ -- Biond Biologics Ltd. ("Biond" or the "Company"), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of biologics, today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35 , a humanized ILT3/LILRB4 antagonist antibody. The first patient was administered BND-35 as a monotherapy at the Institute of Oncology, Davidoff Center, Rabin Medical Center, Israel , one of the six Israel and US trial study sites. The phase 1, open-label, dose escalation study aims to explore the safety, tolerability, anti-tumor activity, pharmacokinetics and exploratory biomarkers for BND-35 as a monotherapy and in combination with two approved drugs, a PD-1/PD-L1 inhibitor or the anti-EGFR drug, cetuximab. The
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- 3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1% [Yahoo! Finance]Yahoo! Finance
- Ruder Finn Group Honored With 7 2024 Bulldog PR Awards [Yahoo! Finance]Yahoo! Finance
- Real-World Evidence and Market Access Annual In-Person Conference (Germany - October 14-15th, 2024): Anticipated Regulatory Updates and RWE Impact on Market Access [Yahoo! Finance]Yahoo! Finance
- Formation Bio secures $372m funds for AI-driven drug platform [Yahoo! Finance]Yahoo! Finance
- Vigil Neuroscience jumps 34% as Sanofi invests $40M [Seeking Alpha]Seeking Alpha
SNY
Sec Filings
- 6/11/24 - Form 6-K
- 5/30/24 - Form 6-K
- 5/28/24 - Form 6-K
- SNY's page on the SEC website